# NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

> **NCT00053989** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 41 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases
- Fanconi Anemia
- Aplastic Anemia

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** graft-versus-tumor induction therapy
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **DRUG:** methylprednisolone
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **PROCEDURE:** umbilical cord blood transplantation

## Key facts

- **NCT ID:** NCT00053989
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01-29
- **Primary completion:** 2018-07-19
- **Final completion:** 2018-07-19
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053989, "NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00053989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*